vebicorvir + AB-729

vebicorvir + AB-729 is a **combination therapy** comprising vebicorvir—a first-generation small molecule inhibitor of the hepatitis B virus (HBV) core protein—and AB-729, a GalNAc-conjugated small interfering RNA (siRNA) targeting all HBV RNA transcripts[1][3][5]. Vebicorvir inhibits HBV replication by interfering with the assembly and function of the viral capsid protein, resulting in deeper reductions in HBV DNA and RNA[3][5]. AB-729 reduces expression of all HBV proteins and antigens, including hepatitis B surface antigen (HBsAg), thereby facilitating reactivation of the patient’s immune response against HBV[2][3]. The combination is administered to virologically suppressed, HBeAg-negative chronic HBV patients as part of investigational regimens aiming to suppress viral replication, induce reduction or loss of HBsAg, restore HBV-specific immunity, and improve the potential for a functional cure. The most common regimen tested is oral vebicorvir (300 mg once daily) and subcutaneous AB-729 (60 mg once every eight weeks), sometimes together with a nucleos(t)ide analog reverse transcriptase inhibitor (NrtI)[1][5]. The combination is currently under investigation primarily in Phase 2a clinical trials[1][5].

Other names

vebicorvir + AB-729